Heparin-induced thrombocytopenia: a practical review

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Heparin-induced thrombocytopenia (HIT) is under-recognized but has severe consequences.
• HIT involves heparin-platelet factor 4 antibodies, leading to platelet activation and thrombosis.
• Thrombosis is the primary cause of vascular complications in HIT.

Purpose of the Study:

• To highlight the importance of recognizing HIT.
• To emphasize timely diagnosis and treatment of HIT.
• To discuss management strategies for HIT, especially in cardiac patients.

Main Methods:

• Review of clinical and serologic clues for HIT diagnosis.
• Discussion of treatment protocols for HIT, including cessation of heparin and use of direct thrombin inhibitors.
• Evaluation of diagnostic tests for HIT, noting their confirmatory role.

Main Results:

• HIT prevalence differs between surgical and medical populations.
• Thrombosis is a key feature of HIT, necessitating prompt suspicion after heparin exposure.
• Delayed HIT treatment can lead to catastrophic outcomes.

Conclusions:

• Early recognition of HIT, incorporating clinical and serologic findings, is paramount.
• Treatment involves stopping heparin and initiating antithrombotic therapy, often with direct thrombin inhibitors.
• Vigilance of platelet counts is essential during heparin therapy, particularly in cardiac patients.